Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Check Cap Ltd (CHEK)

NASDAQ
Currency in USD
Disclaimer
2.2200
-0.0650(-2.84%)
Closed
After Hours
2.2100-0.0100(-0.4505%)

CHEK Comments

What’s going on really 🥹🥹🥹
$10 in few weeks! (after r/s)
today is the day!
What is the good news ?
This is an easy $2.50 stock on trials ending
Clinical trials begin April 15th 2022
How is the outlook short and long term ?
Fda approval of pivotal study!!!
We may see the moon soon
Countdown..
Com’oooon maaan!!!!
For those new to Check Cap Here are some key pointsCheck Cap's C-Scan pill for colonoscopy has been approved for use in Isreal since 2018. https://www.prnewswire.com/news-releases/check-cap-receives-approval-from-the-israeli-ministry-of-health-to-initiate-commercial-sales-in-israel-of-its-c-scan-system-300706973.htmlCheck Cap's Scan tech requires no preparatory procedure which makes follow through with the procedure much easier and less impactful to individual's lives. Patients do not have to experience pain and discomfort from procedure like they do colonoscopies. They also do not need the same facility use as a colonoscopy allowing people to save time.The FDA is particularly interested in Chek because roughly 40% of Americans who should get a colonoscopies don't. Existing non-invasive colon screening is less acurate than C-scan Tech used by Check Cap.Recent study https://www.businesswire.com/news/home/20150428006203/en/New-Study-Reveals-People-Avoid-Colonoscopy
28 percent do not feel it is necessary20.1 percent say it’s too expensive20.1 percent dislike the procedure itself (addressed by Check Cap)15.8 percent rely on other methods to avoid colon cancer (addressed by Check Cap)6.5 percent do not know they are supposed to get one6.5 percent are too busy with other priorities (addressed by Check Cap)Additionally Chek has already raised a large amount of capitolthis year that it expects will carry it through a stage 3 study for the US. Simplywall.st reports they should have enough capitol for 3 years of funding, but this does not account for large scale studies like a phase II and III trial. Covid delayed C-Scan US clinical testing as the FDA was unable to get to Israel in order to inspect the facility.Covid also highlighted challenges to Check Cap's supply chain as they previously used a single supplier, this is something management has been addressing and they have expressed confidence that their expansion and supply chain changes wi
Com’on soon the trials will be starting!!!We are almost there!!
when they will start? thanks
by the end of march
Inthought they were going to let it stay over 1 dollar for at least ten days..
just YOLOed 1.5k on this
Com’ooonn im with you check..Get to 20 dollars and bring me to early retirement :)
🛰
🚀
✈️
Granted patent in US last week!!
Looks like they sent put a news on the pumping of production for the trials at the end of march 2022..Hold it tight!.. march is not that far ;)
Why has the price fallen so extremely in 2015 ($60-70) until today?
the whole market is falling, the institutions are growing from 5% to 10% in 2 months, so all the shares that you are selling now, they have bought. SO... DO NOT SELL YOUR SHAREEEEESSSS!!!!
Still here? My opinion... They will launch this device in America, Europe and Israel in the same time.Price will explode but first will go to 4 - 5 $ when they will start testing it.After the fda big approval will go easily over 10$, hope they will not split it...
Good morning
Whats going on
my average is up 4 soon
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.